Want to see RCUS full AI Analyst Report?
RCUS Stock Chart & Stats
$24.25
-$0.04(-0.26%)
At close: 4:00 PM EST
$24.25
-$0.04(-0.26%)
Day’s Range― - ―
52-Week Range$8.84 - $31.74
Previous CloseN/A
Volume107.84K
Average Volume (3M)1.41M
Market Cap
$3.54B
Enterprise Value$2.00K
Total Cash (Recent Filing)$822.00M
Total Debt (Recent Filing)$113.00M
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Aug 05, 2026EPS Estimate
-0.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.17
Shares Outstanding125,773,160
10 Day Avg. Volume879,792
30 Day Avg. Volume1,413,556
Financial Highlights & Ratios
PEG Ratio-1.52
Price to Book (P/B)4.06
Price to Sales (P/S)10.36
P/FCF Ratio-5.29
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$39.17Price Target Upside61.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-3.68
Revenue Forecast (FY)$79.95M
Bulls Say, Bears Say
Bulls Say
Strong Cash RunwayA large cash balance and explicit runway into 2028 materially reduce near-term refinancing risk and give management time to execute registrational trials and prioritized programs. This funding buffer supports planned PEEK‑1 enrollment, staged readouts, and focused portfolio spend through 2027 without immediate dilution.
Clinical Differentiation Of CascadifanMeaningfully longer PFS and improved ORR versus a comparator indicate durable clinical differentiation for cascadifan, underpinning a strong commercial positioning. Differentiated efficacy increases likelihood of regulatory and payer interest and supports the sizable peak sales assumptions tied to registrational PEEK‑1 success and frontline expansion.
Manageable Leverage And CapitalizationModerate debt relative to equity provides balance-sheet flexibility versus many early‑stage peers, allowing the company to access financing or transact without overleveraging. While equity has declined from prior periods, current capitalization supports continued R&D and partnership options while limiting refinancing strain in the medium term.
Bears Say
High Cash BurnSustained, large negative operating and free cash flow indicates structural cash burn that creates ongoing funding dependence. If trial timelines slip or revenue underperforms, the company may need to raise capital or cut programs, which can dilute shareholders or delay development milestones and commercialization plans.
Persistent Operating LossesDespite high gross margins, persistent multi‑hundred‑million dollar net losses and a modest, fading top line imply limited near‑term path to profitability. Continued negative earnings erode equity and constrain reinvestment flexibility unless clinical successes translate into material revenue or non‑dilutive partnership funding.
Gilead Partnership Reset And Trial DiscontinuationThe discontinuation of STAR‑121 and Gilead's decision not to extend broader option rights narrows external development support and potential milestone revenue. Loss of partner optionality reduces de‑risking for non‑cascadifan assets and may shift more execution and funding burden back to Arcus for remaining programs.
Arcus Biosciences News
RCUS FAQ
What was Arcus Biosciences’s price range in the past 12 months?
Arcus Biosciences lowest stock price was $8.84 and its highest was $31.73 in the past 12 months.
What is Arcus Biosciences’s market cap?
Arcus Biosciences’s market cap is $3.54B.
When is Arcus Biosciences’s upcoming earnings report date?
Arcus Biosciences’s upcoming earnings report date is Aug 05, 2026 which is in 14 days.
How were Arcus Biosciences’s earnings last quarter?
Arcus Biosciences released its earnings results on May 05, 2026. The company reported -$1.02 earnings per share for the quarter, missing the consensus estimate of -$0.88 by -$0.14.
Is Arcus Biosciences overvalued?
According to Wall Street analysts Arcus Biosciences’s price is currently Undervalued.
Does Arcus Biosciences pay dividends?
Arcus Biosciences does not currently pay dividends.
What is Arcus Biosciences’s EPS estimate?
Arcus Biosciences’s EPS estimate is -0.89.
How many shares outstanding does Arcus Biosciences have?
Arcus Biosciences has 125,773,160 shares outstanding.
What happened to Arcus Biosciences’s price movement after its last earnings report?
Arcus Biosciences reported an EPS of -$1.02 in its last earnings report, missing expectations of -$0.88. Following the earnings report the stock price went down -0.23%.
Which hedge fund is a major shareholder of Arcus Biosciences?
Currently, no hedge funds are holding shares in RCUS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arcus Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.17 (61.51% Upside)
$39.17 (61.51% Upside)
Blogger Sentiment
Bullish
RCUS Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 394.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 3.7%
Last 30 Days ▲ 3.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
207.86%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.75%
Trailing 12-Months
Company Description
Arcus Biosciences
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
RCUS Stock 12 Month Forecast
Average Price Target
$39.17
▲(61.51% Upside)
Technical Analysis
Ownership Overview
4.39% Insiders
14.74% Mutual Funds
0.12% Other Institutional Investors
61.32% Public Companies and
Individual Investors